News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis Ophthalmics AG (NVS) Gets Canadian License For Eye Disorder Treatment



6/22/2006 10:39:00 AM

Novartis AG's (NVS) eye health unit received an exclusive license to sell Lucentis in Canada under an amended contract with Genentech Inc. (DNA). Novartis said Thursday Lucentis is used for the treatment of wet, age-related macular degeneration. The disorder is a major cause of central vision loss and is the leading cause of severe blindness in Canada for people who are more than 50 years old.


Read at Market Watch


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES